Stryker Corporation Asia Pacific revenue
Asia Pacific revenue at Stryker Corporation came to $2.2B for the fiscal year to 31 Dec 2025, up 7.1% from a year earlier.
As Stryker Corporation reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 11 Feb 2026.
By fiscal year
| Period ending | Asia Pacific revenue | Change on a year | Filed |
|---|---|---|---|
| 31 Dec 2025 | $2.2B | up 7.1% | 11 Feb 2026 |
| 31 Dec 2024 | $2.0B | up 3.8% | 12 Feb 2025 |
| 31 Dec 2023 | $1.9B | up 3.2% | 14 Feb 2024 |
| 31 Dec 2022 | $1.9B | down 4.5% | 10 Feb 2023 |
| 31 Dec 2021 | $2.0B | up 21.0% | 11 Feb 2022 |
| 31 Dec 2020 | $1.6B | up 0.8% | 11 Feb 2021 |
| 31 Dec 2019 | $1.6B | up 5.5% | 6 Feb 2020 |
| 31 Dec 2018 | $1.5B | up 8.4% | 7 Feb 2019 |
| 31 Dec 2017 | $1.4B | up 6.6% | 8 Feb 2018 |
| 31 Dec 2016 | $1.3B | up 5.9% | 9 Feb 2017 |
| 31 Dec 2015 | $1.3B | down 8.6% | 11 Feb 2016 |
| 31 Dec 2014 | $1.4B | up 3.7% | 12 Feb 2015 |
| 31 Dec 2013 | $1.3B | down 1.3% | 13 Feb 2014 |
| 31 Dec 2012 | $1.3B | — | 27 Feb 2013 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Stryker Corporation: Organic net sales (change on a year) · Neuro Cranial Instruments revenue · Orthopaedic Instruments revenue · Neuro Cranial - Interventional Spine revenue · Enabling Technologies revenue · Medical revenue · Endoscopy revenue · Trauma and Extremities revenue · Instruments revenue · Instruments (earlier basis) revenue · Ortho Tech revenue · Neuro Cranial revenue · Knees revenue · Vascular revenue · Hips revenue · Spinal Implants revenue · MedSurg and Neurotechnology (revenue) · Orthopaedics (revenue) · United States revenue · Europe, Middle East, Africa revenue · International revenue · financial statements
Every KPI and segment of SYK, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
